Targeting T cells
By selectively targeting well differentiated T cells that express killer cell lectin like receptor G1 (KLRG1) – a cell type that has not been exclusively targeted before – we believe our novel approach will result in the depletion of these pathogenic cells in order to address T cell driven autoimmune diseases.
T Cell Depletion with Ulviprubart
- Target KLRG1 on highly cytotoxic T cells
- Highly cytotoxic T cells are responsible for autoimmune disease
- Ulviprubart is specific to these T cells that express KLRG1
- By depleting these T cells, we believe we can impact pathogenesis of the autoimmune diseases
Our focus starts with Inclusion Body Myositis (IBM) but we believe our approach could have applications across many autoimmune indications.
